EF Hutton Maintains Buy on Marinus Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Marinus Pharma (NASDAQ:MRNS) and maintained a price target of $23.
October 17, 2024 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Marinus Pharma and maintained a price target of $23, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a maintained price target of $23 by EF Hutton suggests a positive outlook for Marinus Pharma. This can lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100